---
title: "Alzamend Neuro issues 361,743 shares on conversion of Series B preferred stock"
url: "https://aibio.space/news/alzamend-neuro-issues-361-743-shares-conversion-series-b-preferred/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-10-09"
section: "Financings"
tickers: "NASDAQ:ALZN"
source: "https://www.sec.gov/Archives/edgar/data/1677077/000121465925014818/o1082528k.htm"
summary: "The shares were issued between October 1, 2025 and October 8, 2025. The company had 3,801,604 common shares outstanding as of October 8, 2025."
---

By the aibio.space news desk.

Sources

- [Alzamend Neuro, Inc. 8-K (2025-10-09)](https://www.sec.gov/Archives/edgar/data/1677077/000121465925014818/o1082528k.htm)

[ALZN](https://aibio.space/companies/alzamend-neuro/)

2025-10-09

# Alzamend Neuro issues 361,743 shares on conversion of Series B preferred stock

Tickers [ALZN](https://aibio.space/companies/alzamend-neuro/)

The shares were issued between October 1, 2025 and October 8, 2025. The company had 3,801,604 common shares outstanding as of October 8, 2025.

## Key facts

- **Company**: Alzamend Neuro, Inc. (NASDAQ: ALZN)

- **News type**: Financings

- **Primary source**: [Alzamend Neuro, Inc. 8-K (2025-10-09)](https://www.sec.gov/Archives/edgar/data/1677077/000121465925014818/o1082528k.htm)

*Glass office towers seen from below. CC0, via rawpixel. The picture shows the field, not the companies named.*

Alzamend Neuro, Inc. (Nasdaq: [ALZN](https://aibio.space/companies/alzamend-neuro/)) issued an aggregate of 361,743 shares of common stock between October 1, 2025 and October 8, 2025, according to an [8-K filed October 9, 2025](https://www.sec.gov/Archives/edgar/data/1677077/000121465925014818/o1082528k.htm).

The shares were issued on conversion of approximately 839.2 shares of Series B Convertible Preferred Stock. Convertible preferred stock is a class of shares that holders can exchange for common stock under set terms. Each conversion adds common shares and spreads ownership across a larger share count.

The company said the shares were issued without SEC registration, relying on the exemption in Section 4(a)(2) of the Securities Act.

As of October 8, 2025, the Atlanta, Georgia company had 3,801,604 shares of common stock outstanding. Its common stock trades on The Nasdaq Capital Market.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

ALZN

Alzamend Neuro, Inc.

NASDAQ · United States

Open the starter desk

## More in Financings

Financings

### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/)

Oct 29, 2026

Financings

### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/)

Oct 29, 2026

Financings

### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/)

Oct 29, 2026

---
Source page: https://aibio.space/news/alzamend-neuro-issues-361-743-shares-conversion-series-b-preferred/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Alzamend Neuro issues 361,743 shares on conversion of Series B preferred stock", 2025-10-09, https://aibio.space/news/alzamend-neuro-issues-361-743-shares-conversion-series-b-preferred/